ABSTRACT
34 male peptic ulcer patients were compared to (a) a group of 37 healthy controls and (b) a group of 36 hospitalized controls suffering from illnesses unrelated to the gastrointestinal tract. Patients and controls were submitted to the Eysenck personality inventory, Foulds' hostility questionnaire, Langner's 22-item questionnaire, the Hopkins symptom checklist, Zung's self-rating anxiety scale, Spielberger's state-trait anxiety inventory, Zung's and Beck's rating scales for depression, and the 43-item life event inventory by Holmes and Rahe. All patients suffered from duodenal ulcer. The parameters that differentiated to a statistically significant degree the peptic ulcer patients from either one or both groups of controls were: (a) neuroticism, (b) trait and state anxiety, (c) guilt, (d) general psychopathology, and (e) stressful life events. Additionally, more than 50% of patients had at least one first-degree relative with peptic ulcer. These observations indicate that psychopathological, psychosocial, characterological and hereditary factors are important pathogenetic contributors in peptic ulcer.
Subject(s)
Duodenal Ulcer/psychology , Personality Disorders/psychology , Social Environment , Adult , Anxiety Disorders/psychology , Depressive Disorder/psychology , Duodenal Ulcer/genetics , Humans , Life Change Events , Male , Personality Inventory , PsychometricsABSTRACT
In an open clinical trial, Ro 11-1163, a newly developed MAO inhibitor, was given to 11 depressed patients, in a flexible dose, for 6 weeks. The clinical effect was measured on the 3rd day and at weekly intervals using the Hamilton and the Beck rating scales for depression and an overall self-assessment. A marked antidepressant effect was observed in almost all cases, which became evident as early as the 2nd day and resulted in complete remission in most patients at the end of the treatment period, with doses ranging between 100 and 400 mg/day. No serious side effects were noted, except for a transient agitation and insomnia. A battery of clinical and laboratory tests also failed to reveal any marked change during treatment. The results suggest that Ro 11-1163 is an effective antidepressant that has to be further evaluated by double-blind clinical trials.
Subject(s)
Benzamides/therapeutic use , Depressive Disorder/drug therapy , Monoamine Oxidase Inhibitors/therapeutic use , Adult , Benzamides/administration & dosage , Benzamides/adverse effects , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Clinical Trials as Topic , Depressive Disorder/psychology , Female , Humans , Male , Middle Aged , Moclobemide , Monoamine Oxidase Inhibitors/administration & dosage , Monoamine Oxidase Inhibitors/adverse effects , Personality InventoryABSTRACT
In a controlled study the activity of glucose-6-phosphate dehydrogenase (G-6-PD) in red and white blood cells, gamma-glutamyl transpeptidase (gamma-GT) and lysozyme in serum and white blood cells was studied in 22 drug-free schizophrenic patients and 17 healthy volunteers. The activities of the above enzymes were found to be reduced in the white cells of schizophrenics compared with controls. The differences in activity of G-6-PD in red cells and of gamma-GT and lysozyme in serum between the two groups were not revealed as significant. The observed low enzyme activities might provide a further basis for interpreting the reported functional deficiency in neutrophils of schizophrenics. Possible mechanisms in relation to biological abnormalities in schizophrenia are discussed.
